TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04485650

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: music therapy
Description: The music were chosen by a researcher under guidance of an expert and grouped as relaxing, classical, mystical, and Turkish folk music. One of them was chosen by the patients following the application of spinal anesthesia in the music group.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: sedated group
Description: Sedation was performed to the sedated group after spinal anesthesia based on the height and weight data and the doctor's decision. The number of participants:30

Intervention type: OTHER
Group type: OTHER
Intervention: non-sedated group
Description: The patients in the non-sedated group were followed without any procedure (sedation and music). The number of participants:30
Study: NCT00547911

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Droxidopa

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Droxidopa

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Droxidopa

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Droxidopa

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Droxidopa

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Droxidopa

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carbidopa

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carbidopa

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carbidopa

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carbidopa

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carbidopa

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carbidopa
Study: NCT01453478

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1325756
Description: CXCR2 antagonist

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1325756
Description: CXCR2 antagonist
Study: NCT00057304

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO 205-2349

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO 205-2349
Study: NCT00815815

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Structured Behavioral Treatment
Description: Daily therapy sessions and a weight gain protocol involving set meals and exercise levels

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Structured Behavioral Treatment
Description: Daily therapy sessions and a weight gain protocol involving set meals and exercise levels
Study: NCT00547911

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entacapone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entacapone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entacapone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entacapone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entacapone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entacapone
Study: NCT01078662

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: olaparib
Description: Tablets Oral BID
Study: NCT03363659

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Disulfiram
Description: Disulfiram is taken orally, twice daily.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Copper gluconate
Description: Copper gluconate is taken orally, twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Temozolomide is taken once daily
Study: NCT03408743

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Knowledge Alone
Description: Increase knowledge relate d STIs, STI risk, alcohol impairment, condom use skills, alcohol use behavior tracking skills, testing \& treatment services.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-efficacy alone
Description: Increase self-efficacy to us e protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Perceived benefits alone
Description: Increase perceived benefits to use protective behavioral strategies to reduce the negative consequences of engaging in sexual behaviors under the influence of alcohol.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Benefits and self-efficacy
Description: Increase perceived benefits to use protective behavioral strategies to reduce the negative consequences of engaging in sexual behaviors under the influence of alcohol and increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Injunctive norms alone
Description: Correct misperceptions regarding approval of alcohol misuse \& sexual risk taking.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Injunctive norms and self-efficacy
Description: Correct misperceptions regarding approval of alcohol misuse \& sexual risk taking and increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Injunctive norms and benefits
Description: Correct misperceptions regarding approval of alcohol misuse \& sexual risk taking and increase perceived benefits to use protective behavioral strategies to reduce the negative consequences of engaging in sexual behaviors under the influence of alcohol and increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Injunctive norms, benefits, self-efficacy
Description: Correct misperceptions regarding approval of alcohol misuse \& sexual risk taking; increase perceived benefits to use protective behavioral strategies to reduce the negative consequences of engaging in sexual behaviors under the influence of alcohol and increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex; and increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Descriptive norms alone
Description: Correct misperceptions of prevalence of alcohol-induced sexual risk behaviors, alcohol use/misuse, and sexual risk behaviors.
Study: NCT03671109

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine (DHA-PPQ)
Description: Following physical examination, recruited women with more than 13 weeks of gestational age will receive IPTp-DHA-PPQ under supervision

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Following physical examination, recruited women with more than 13 weeks of gestational age will receive IPTp-Placebo under supervision
Study: NCT03141710

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 20 ml of prebiotic per day
Description: 12 volunteers will take 20ml of prebiotic per day for 12 weeks
Study: NCT01337830

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ariva® Silver Wintergreen
Description: Study product containing 6 mg silver salt and 2 mg nicotine per dissolvable lozenge, administered orally as a single dose.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Silver Wintergreen
Description: Comparator product containing 6 mg silver salt and no tobacco (i.e., no nicotine), administered orally as a single dose.
Study: NCT04360174

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OTX-TIC
Description: OTX-TIC implant is injection in the anterior chamber of the eye

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OTX-TIC
Description: OTX-TIC implant is injection in the anterior chamber of the eye

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OTX-TIC
Description: OTX-TIC implant is injection in the anterior chamber of the eye

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OTX-TIC
Description: OTX-TIC implant is injection in the anterior chamber of the eye
Study: NCT03452046

Intervention type: OTHER
Intervention: IVC diametres

Intervention type: OTHER
Intervention: IVC diametres

Intervention type: OTHER
Intervention: IVC diametres

Intervention type: OTHER
Intervention: IVC diametres
Study: NCT01919684

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LGD-6972

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Captisol®)
Study: NCT02876991

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Sodium fluoride PET
Description: Sodium fluoride Pet is realized maximum after 4 weeks from choline PET (inclusion).~Injection of 4MBq 18F-FNa/kg of body weight is followed after 60 min (± 5 min) by acquisition of images on Biograph 6 PET/CT scanner (SIEMENS).~Data from sodium fluoride PET are interpreted independently and blind from other data by 3 medical doctors (2 at hospital of Nancy and 1 at hospital of Strasbourg) (for inter-judge reproducibility); a second interpretation of data is consensually realized by 2 of 3 readers, limited to discordant analyses (metastatic status or not, and/or number of lesions); results from this second interpretation are final results.
Study: NCT04699513

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mechanical Ventilation Mode (airway pressure release ventilation )
Description: Airway pressure release ventilation (APRV) is a mode of mechanical ventilation that alternates between two levels of continuous positive airway pressure (CPAP) support and allows spontaneous respiratory effort at either CPAP level. It is considered as an alternative, life-saving modality in patients with acute respiratory distress syndrome (ARDS) that struggle for oxygenation.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mechanical Ventilation Mode (airway pressure release ventilation )
Description: Airway pressure release ventilation (APRV) is a mode of mechanical ventilation that alternates between two levels of continuous positive airway pressure (CPAP) support and allows spontaneous respiratory effort at either CPAP level. It is considered as an alternative, life-saving modality in patients with acute respiratory distress syndrome (ARDS) that struggle for oxygenation.
Study: NCT03184194

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nivolumab-daratumumab
Description: nivolumab-daratumumab will be given without low-dose cyclophosphamide until progression

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nivolumab-daratumumab with low-dose cyclophosphamide
Description: nivolumab-daratumumab with low-dose cyclophosphamide will be given until progression
Study: NCT03931473

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Bed nets
Description: Next-generation bed nets combining insecticides with different modes of action or a standard pyrethroid bed net

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bed nets
Description: Next-generation bed nets combining insecticides with different modes of action or a standard pyrethroid bed net

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bed nets
Description: Next-generation bed nets combining insecticides with different modes of action or a standard pyrethroid bed net
Study: NCT00369070

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: 15 mg/kg bevacizumab, delivered via intravenous (IV) infusion once every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 706
Description: subjects in Arms A and B will take AMG 706 orally in one of two dosing regimens over each 21-day cycle: •Arm A: 125 mg once daily (QD) •Arm B: 75 mg twice daily every 12 ± approximately 1 hour for 5 days followed by a 2 day treatment free period every 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 706
Description: subjects in Arms A and B will take AMG 706 orally in one of two dosing regimens over each 21-day cycle: •Arm A: 125 mg once daily (QD) •Arm B: 75 mg twice daily every 12 ± approximately 1 hour for 5 days followed by a 2 day treatment free period every 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: All subjects will receive a paclitaxel chemotherapy regimen (paclitaxel 200 mg/m2) on day 1 of each 3-week cycle for a maximum of 6 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: All subjects will receive a paclitaxel chemotherapy regimen (paclitaxel 200 mg/m2) on day 1 of each 3-week cycle for a maximum of 6 cycles.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: All subjects will receive a paclitaxel chemotherapy regimen (paclitaxel 200 mg/m2) on day 1 of each 3-week cycle for a maximum of 6 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: All subjects will receive carboplatin chemotherapy regimen (carboplatin at AUC of 6 mg/mL x min) on day 1 of each 3-week cycle for a maximum of 6 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: All subjects will receive carboplatin chemotherapy regimen (carboplatin at AUC of 6 mg/mL x min) on day 1 of each 3-week cycle for a maximum of 6 cycles.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: All subjects will receive carboplatin chemotherapy regimen (carboplatin at AUC of 6 mg/mL x min) on day 1 of each 3-week cycle for a maximum of 6 cycles.
Study: NCT00847769

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High velocity, low amplitude stretch
Description: This group (n=9) will receive talocrural traction manipulation. With the subject in a seated position on a treatment table and the lower extremity of interest stabilized to the table with a belt, a single standardized treating investigator will grasp the foot of interested with the thenar eminences on the foot's plantar surface. A thrust will be delivered parallel to the long axis of the subject's lower leg after the treating therapist induces passive ankle dorsiflexion to end range.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Slow, mobilization stretch
Description: This group (n=9) will receive talocrural traction mobilization. With the subject in a seated position on a treatment table and the lower extremity of interest stabilized to the table with a belt, a single standardized treating investigator will grasp the foot of interested with the thenar eminences on the foot's plantar surface. Traction will be delivered to the talocrural joint at the treating investigator's second perception of tissue resistance in 3 bouts of 30-second holds, separated by 10 seconds of rest.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Passive Positioning
Description: This group (n=9) will receive the manual therapy control intervention. This will consist of the same patient and clinician preparation for the mobilization/manipulation techniques. However, a single standardized treating investigator will simply maintain passive ankle positioning for the duration of 1 deep inhalation and exhalation by the subject rather than induce an iatrogenic force characteristic of the intervention received by the other 2 comparison groups.
Study: NCT06586788

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Eyelink Portable Duo
Description: Eye-tracking data will be collected using a commercially-available remote eye-tracking system (Eyelink Portable Duo). Eye movements and pupil diameter will be collected while participants view a series of developmentally appropriate pictures and movies. The eye-tracker consists of two cameras; one that monitors eye movements and a second scene camera that monitors head movements, which permits eye tracking to take place without any equipment touching the child. Children will be asked to sit in highchair or on a caregiver's lap and will face a computer monitor. After a sticker is applied to the child's forehead and brief eye-movement calibration completed, next visual stimuli (i.e., pictures and videos) will be presented on a laptop computer monitor that is placed at approximately 60-80cm from the child. The eye tracking portion of the visit will last approximately 15 minutes or until the child is no longer able to attend to pictures/videos.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Integrated PCP Diagnosis and Eye-tracking Biomarker
Description: A Classification and Regression Tree (CART) Analysis, based on recursive partitioning, was used to determine which combination of variables (EE Hub PCP diagnosis, diagnostic certainty, composite biomarker, and biomarker frequency \[sum of all individual biomarkers (0-6) that exceeded the 95% specificity threshold for each child\]) best predicted reference standard autism diagnosis.
Study: NCT02490891

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RGD K5 PET scan
Description: PET scan with a tracer specific for angiogenesis (RGD K5) will be performed before and after 2 cycles of chemotherapy
Study: NCT02679534

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: hand massage

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: hand holding

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: application of unscented hypoallergenic cream

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: application of unscented hypoallergenic cream

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: environmental adjustments

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: environmental adjustments

Intervention type: OTHER
Group type: OTHER
Intervention: environmental adjustments
Study: NCT01338558

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab [Avastin]
Description: 5 mg/kg iv on Day 1 of each 2-week cycle until disease progression, unacceptable toxicity or withdrawal of consent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab [Avastin]
Description: 5 mg/kg iv on Day 1 of each 2-week cycle until disease progression, unacceptable toxicity or withdrawal of consent

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cetuximab
Description: 400 mg /m2 iv on Day 1, followed by 250 mg/m2 every week until disease progression, unacceptable toxicity or withdrawal of consent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mFOLFOX6
Description: Standard mFOLFOX6 chemotherapy, 2-week cycles until disease progression, unacceptable toxicity or withdrawal of consent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mFOLFOX6
Description: Standard mFOLFOX6 chemotherapy, 2-week cycles until disease progression, unacceptable toxicity or withdrawal of consent

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mFOLFOX6
Description: Standard mFOLFOX6 chemotherapy, 2-week cycles until disease progression, unacceptable toxicity or withdrawal of consent
Study: NCT03055611

Intervention type: DRUG
Intervention: ELOCTA
Description: Extended half-life factor VIII product

Intervention type: DRUG
Intervention: ALPROLIX
Description: Extended half-life factor IX product
Study: NCT01052909

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glimepiride
Description: Glimepiride tablets 1 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glimepiride
Description: Glimepiride tablets 1 mg
Study: NCT03820479

Intervention type: OTHER
Intervention: Protocol
Description: Best practice of protocol

Intervention type: OTHER
Intervention: Protocol
Description: Best practice of protocol

Intervention type: OTHER
Intervention: Protocol
Description: Best practice of protocol

Intervention type: OTHER
Intervention: Protocol
Description: Best practice of protocol
Study: NCT04147767

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cholesterol Reducing Strawberry Yogurt Drink (Tesco Ltd)
Description: Ingredients: Skimmed Milk, Strawberry Juice from Concentrate (5%), Plant Sterols Ester (3.4%)\*\*\*, Sugar, Maize Starch, Flavourings, Colour (Anthocyanins), Starter Culture including Bifidobacterium (Milk), Thickener (Carob Gum), Sweetener (Sucralose), Milk Proteins.~\*\*\* Equivalent to 2% Free Plant Sterols

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Low Fat Strawberry Yogurt Drinks (Morrisons Ltd)
Description: Ingredients: Yogurt (Milk), Water, Sugar, Strawberry Purée (1%), Modified Maize Starch, Carrot Concentrate, Flavouring, Acidity Regulator (Citric Acid), Vitamin C, Colour (Paprika Extract), Sweetener (Sucralose), Vitamin D, Vitamin B6.
Study: NCT03966690

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Isokinetic leg extension/-flexion on a legpress device
Description: Maximum strength and rate of leg-flexion /-extension during legpress exercise

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Isokinetic leg extension/-flexion on a legpress device
Description: Maximum strength and rate of leg-flexion /-extension during legpress exercise

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Isokinetic leg extension/-flexion on a legcurl device
Description: Maximum strength and rate of leg-flexion /-extension during legcurl exercise

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Isokinetic leg extension/-flexion on a legcurl device
Description: Maximum strength and rate of leg-flexion /-extension during legcurl exercise
Study: NCT03264768

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: endobronchial valves
Description: A ambulatory diagnostic bronchoscopy under general anesthesia will evaluate the presence or absence of collateral ventilation . The targeted lobar airway is temporarily occluded by means of a balloon catheter, which blocks inspiratory flow but allows expiratory flow, in order to assess whether the air flow gradually declines to zero, meaning absence of collateral ventilation. Only in case collateral ventilation is excluded, a therapeutic bronchoscopy will be scheduled to insert the one-directional endobronchial valves in the targeted lobar airways. We will only perform a unilateral intervention during which we will treat one or maximal two lobes at one side.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: physical activity tele coaching
Description: 3 month physical activity tele coaching intervention consisting of a project tailored smartphone application in combination with a step counter providing direct feedback.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: physical activity tele coaching
Description: 3 month physical activity tele coaching intervention consisting of a project tailored smartphone application in combination with a step counter providing direct feedback.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lung volume reduction surgery (LVRS)
Description: Patients not eligible for endoscopic lung volume reduction (or non responders of this intervention) can be referred for surgical lung volume reduction. With this procedure, the most emphysematous parts of the lungs will be surgically removed.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Lung volume reduction surgery (LVRS)
Description: Patients not eligible for endoscopic lung volume reduction (or non responders of this intervention) can be referred for surgical lung volume reduction. With this procedure, the most emphysematous parts of the lungs will be surgically removed.